Company intelligence / Profile preview
TheraPPI Bioscience
Lyon, Auvergne-Rhône-Alpes, Francetppibio.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
TheraPPI is a preclinical-stage biotech developing small molecule drugs that modulate novel protein-protein interactions within the RAS-MAPK pathway. Their lead programs aim to overcome cancer resistance and improve outcomes for advanced cancers and rare diseases. The company has received recognition such as the French Tech Seed label for its innovation.
- Therapeutic areas
- ImmunologyOncologyRare Diseases
- Modalities
- Small molecules targeting protein-protein interactions (PPIs)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Collaborations with academic institutions including CRCL (Université Claude Bernard Lyon I, Inserm, Centre Léon Bérard, CNRS) and C3D technology platform of Lyon.
Beyond the preview
Go deeper on TheraPPI Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TheraPPI Bioscience.